In oncology, there are a variety of potential clinical applications for a minimally invasive blood test for DNA released from tumor cells. Such applications include detecting early stage disease, tracking response to therapy, prompt identification of disease relapse or recurrence, and recognition of clonal evolution.  Numerous small-scale studies have demonstrated that quantitation of mutations in circulating tumor DNA (ctDNA) is feasible from the blood of cancer patients. The increased adoption of targeted cancer therapies underscores the need to augment invasive tissue biopsies with alternative detection methods that rapidly monitor treatment response. Although most studies have been proof of principle, ctDNA methods hold great promise in cancer diagnostics.


Speaker: Christina Lockwood, PhD, DABCC, FACB

Duration: 1.0 hr

Level of Instruction: Basic


All sales are final. No refunds will be issued.

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

Course Information
Course Date:
June 09, 2016
Course Objectives
  • Define circulating, cell-free tumor DNA (ctDNA).
  • Explain the pre-analytic and standardization challenges associated with ctDNA.
  • Summarize the clinical utility of ctDNA in lung cancer and breast cancer.
Promises and Pitfalls of Circulating Tumor DNA
Individual topic purchase: Selected
AMP Regular Member: $0.00
AMP Technologist Member: $0.00
AMP Associate Member: $0.00
Non-member Price: $195.00